Rising prevalence of diabetes and increasing incidences of blindness among people with severe diabetic conditions are expected to fuel the global market growth.
Rising prevalence of diabetes and increasing incidences of blindness among people with severe diabetic conditions are expected to fuel the global market growth
The global diabetic retinopathy market size is expected to reach USD by 15.01 billion 2028 at a CAGR of 7.3%, according to a new report by Reports and Data. Rising prevalence of chronic conditions such as diabetes, increasing cases of diabetic retinopathy among diabetic patients, and growing preferences for technologically advanced and minimally invasive procedures are among the major factors responsible for the growth of the global diabetic retinopathy market in the upcoming years. Booming geriatric population worldwide and their growing susceptibility to chronic diseases such as diabetes, cardiovascular disorders, and sleep disorders further boost market growth to a significant extent.
Diabetic retinopathy is a severe medical condition in which diabetes affects the eyes. The principal cause of diabetic retinopathy is damage to the blood vessels of the light-sensitive tissue of the retina. The most common symptoms of this condition include blurred vision, fluctuating vision, dark or empty areas in the vision, impaired color vision, and vision loss. Excessive amount of sugar in blood leads to the blockage of the tiny blood vessels of the retina and hamper blood supply. Mild-to-moderate cases of diabetic retinopathy may be treated with the help of effective diabetes management; however, advanced cases require laser treatment or surgical procedures.
Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/1484
Some Key Highlights in the Report:
- Non-proliferative diabetic retinopathy segment is projected to register the highest CAGR of 7.5% over the forecast period. Rising prevalence of non-proliferative diabetic retinopathy among diabetic patients is one of the most vital factors driving this segment’s growth.
- On the basis of management, the anti-VEGF segment dominated tin terms of revenue in 2020. The segment is expected to maintain its dominance throughout the forecast period, owing to increasing applications of anti-VEGF drugs including Eylea, Lucentis, Avastin, and Macugen in the treatment of mild-to-moderate cases of diabetic retinopathy is one of the key factors accountable for the growth of this segment.
- Among the various distribution channels, the hospitals segment held the largest revenue share in the global diabetic retinopathy market in 2020. Increasing availability of diagnostic instruments in hospitals and pharmacies worldwide and growing number of treatment procedures for diabetic retinopathy bolster the growth of this segment.
- The North America diabetic retinopathy market is the most dominant regional market in terms of revenue. Growing prevalence of diabetes, increasing use of anti-VEGF drugs including Avastin, Eylea, and Lucentis for diabetic retinopathy, rising patient awareness, and the presence of state-of-the-art healthcare infrastructure in North America are the primary factors accountable for the regional market growth. The Asia Pacific market is the fastest-growing regional market and is expected to display a robust CAGR of 8.3% over the forecast period.
- Novartis AG, Bayer Healthcare, Regeneron Pharmaceuticals Inc., ThromboGenics, Actavis Plc, Sirnaomics, Genentech, Alimera Sciences, Glycadia Pharmaceuticals, Ampio Pharmaceuticals, Kowa Group, and BCN Peptides are some of the renowned companies operating in the global diabetic retinopathy market.
Request for Custom Research @ https://www.reportsanddata.com/request-customization-form/1484
For the purpose of this report, the global diabetic retinopathy market is segmented on the basis of type, disease form, management, distribution channel, and region:
Type (Revenue, USD Billion; 2018-2028)
- Mild
- Moderate
- Severe
Disease Form (Revenue, USD Billion; 2018-2028)
- Proliferative diabetic retinopathy
- Non-proliferative diabetic retinopathy
Management (Revenue, USD Billion; 2018-2028)
- Anti-VEGF
- Intraocular steroid injection
- Laser surgery
- Vitrectomy
Distribution channel (Revenue, USD Billion; 2018-2028)
- Eye clinics
- Hospitals
- Retail pharmacies
- Online pharmacies
- Ambulatory surgical centers
- Other
Buy now your Exclusive copy of Report @ https://www.reportsanddata.com/checkout-form/1484
Regional Outlook (Revenue, USD Billion; 2018-2028)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Rest of the Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- UAE
- Rest of the Middle East & Africa
Explore Reports and Data’s Prime Analysis of the global Healthcare & Pharmaceutical Industry:
Sugar-Based Excipients Market By Type (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), By Application (Powders/Granules, Direct Compression, Crystals, Syrups), And Region - Global Forecasts To 2028
Tapentadol (Palexia) Market By Type (High Purity, Low Purity), By Application (50mg Tablet Product, 75mg Tablet Product, 100mg Tablet Product, Others), By Region - Global Forecasts To 2027
Vitamin PP (Niacin and Niacinamide) Market Size, Share & Analysis, By Grade (Feed Grade, Food Grade, Pharma Grade), By Application (Animal Feeding, Food Additives, Health Supplements, Pharmaceuticals, Others), and By Region, Forecast to 2027
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Read Full Press Release: https://www.reportsanddata.com/press-release/global-diabetic-retinopathy-market